Benefit of using renal sodium-glucose cotransporter inhibitors 2 (iSGLT-2) in patients with type 2 Diabetes Mellitus and Heart Failure. Acervo Saúde. 2020;12(9):e4349. doi:10.25248/reas.e4349.2020